This roundtable series examines combination therapy for treatment-naive patients with unresectable or metastatic hepatocellular carcinoma, as discussed by key opinion leaders and participants at virtual live events.

Monoclonal Antibodies Used in Combination for HCC

Atezolizumab/Bevacizumab Benefit Potentially Extends to Child-Pugh B HCC

June 04, 2024

Stacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.

Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC

May 01, 2024

Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.